Equities analysts expect Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) to report $0.19 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Allscripts Healthcare Solutions’ earnings. The highest EPS estimate is $0.20 and the lowest is $0.18. Allscripts Healthcare Solutions reported earnings per share of $0.16 during the same quarter last year, which indicates a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Allscripts Healthcare Solutions will report full-year earnings of $0.75 per share for the current financial year, with EPS estimates ranging from $0.72 to $0.80. For the next fiscal year, analysts forecast that the business will report earnings of $0.86 per share, with EPS estimates ranging from $0.79 to $0.97. Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings data on Thursday, August 2nd. The software maker reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. The company had revenue of $525.50 million for the quarter, compared to the consensus estimate of $536.93 million. Allscripts Healthcare Solutions had a return on equity of 8.26% and a net margin of 0.10%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS.

A number of research firms have recently issued reports on MDRX. Cantor Fitzgerald reiterated a “buy” rating and issued a $17.00 target price on shares of Allscripts Healthcare Solutions in a research note on Thursday, August 2nd. Canaccord Genuity lowered their target price on Allscripts Healthcare Solutions from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, August 3rd. Royal Bank of Canada reiterated a “buy” rating and issued a $14.00 target price on shares of Allscripts Healthcare Solutions in a research note on Friday, August 3rd. BidaskClub upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Saturday, August 4th. Finally, ValuEngine upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $16.32.

In other news, Director Michael Klayko bought 4,000 shares of the firm’s stock in a transaction dated Wednesday, June 13th. The stock was bought at an average price of $12.52 per share, for a total transaction of $50,080.00. Following the transaction, the director now owns 117,315 shares in the company, valued at $1,468,783.80. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Richard J. Poulton sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $12.40, for a total value of $186,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,000 shares of company stock valued at $609,650. 0.75% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in MDRX. Comerica Bank lifted its position in Allscripts Healthcare Solutions by 3.9% during the 1st quarter. Comerica Bank now owns 171,766 shares of the software maker’s stock valued at $2,126,000 after acquiring an additional 6,467 shares during the period. Boston Partners lifted its position in Allscripts Healthcare Solutions by 0.4% during the 1st quarter. Boston Partners now owns 1,877,232 shares of the software maker’s stock valued at $23,184,000 after acquiring an additional 6,989 shares during the period. Swiss National Bank lifted its position in Allscripts Healthcare Solutions by 2.5% during the 1st quarter. Swiss National Bank now owns 298,700 shares of the software maker’s stock valued at $3,689,000 after acquiring an additional 7,300 shares during the period. Mission Wealth Management LP purchased a new position in Allscripts Healthcare Solutions during the 1st quarter valued at about $135,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Allscripts Healthcare Solutions during the 1st quarter valued at about $596,000.

Shares of Allscripts Healthcare Solutions stock traded down $0.17 during trading hours on Friday, reaching $14.53. The stock had a trading volume of 50,353 shares, compared to its average volume of 1,468,735. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 31.13, a price-to-earnings-growth ratio of 1.91 and a beta of 1.14. The company has a debt-to-equity ratio of 1.41, a current ratio of 0.94 and a quick ratio of 0.94. Allscripts Healthcare Solutions has a 1 year low of $10.78 and a 1 year high of $16.13.

Allscripts Healthcare Solutions announced that its Board of Directors has authorized a share repurchase plan on Thursday, August 2nd that allows the company to buyback $250.00 million in shares. This buyback authorization allows the software maker to reacquire up to 11.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Read More: Do Tariffs Work?

Get a free copy of the Zacks research report on Allscripts Healthcare Solutions (MDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.